Results 221 to 230 of about 693,536 (346)

A new approach to osteoarthritis: gut microbiota. [PDF]

open access: yesRev Assoc Med Bras (1992)
Aydin M, Avci GA, Yilmaz UI, Avci E.
europepmc   +1 more source

Gut microbiota and hypertension [PDF]

open access: yesHypertension Research, 2019
Jun-ichi Oyama, Koichi Node
openaire   +2 more sources

Microbiome‐Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pharmacomicrobiomics is an emerging field due to important microbiome effects on pharmacokinetics and clinical outcomes. However, the application of this knowledge remains limited. Mycophenolic acid (MPA) is the primary active metabolite of the immunosuppressant, mycophenolate mofetil (MMF).
Abdelrahman Saqr   +4 more
wiley   +1 more source

The gut microbiota and aging: interactions, implications, and interventions. [PDF]

open access: yesFront Aging
Gyriki D   +5 more
europepmc   +1 more source

Antibiotic‐Induced Microbial Dysbiosis Worsened Outcomes in the Activity‐Based Anorexia Model

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Anorexia nervosa (AN) is a complex psychiatric disorder characterized by persistent dieting and reduced food intake, leading to significantly low body weight. Dysbiosis in the gut microbiome of patients with AN has been suggested to contribute to the pathogenesis.
Karlijn L. Kooij   +15 more
wiley   +1 more source

Insufficient awareness of celiac disease in China: population-based screening is needed

open access: yesChinese Medical Journal, 2019
Chu-Yan Chen, Jing-Nan Li, Yi Cui
doaj   +1 more source

Flavanones as Modulators of Gut Microbiota and Cognitive Function. [PDF]

open access: yesMolecules
Cichon N   +5 more
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy